Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer
Recent Phase III data presented at the American Society of Clinical Oncology (ASCO) 2013 annual conference by Brose et al led to the US Food and Drug Administration (FDA) approval of sorafenib for the treatment of well-differentiated radioactive iodine-resistant metastatic thyroid cancer. This is th...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2014
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105272/ |